58 results about "Sphingolipid" patented technology

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The present invention provides the use of at least one sphingolipid for a hair treatment for inducing hair growth and / or inhibiting hair loss, including eyelashes and eyebrows. Said sphingolipid is preferably a ceramide having a fatty acid with a long hydrocarbon chain of C18-C24, mostly C20-C22, and a phytosphingosine base. Furthermore, and advantageously, the treatment is global, capable to also improve the properties of the scalp and hair themselves.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).

The application discloses a MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection and a preparation method and a use method thereof, and relates to the technical field of analytical testing. The MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection has the general structure of: the preparation method comprises the following steps: 4-pyridine propionic acid or pyridine 4-propenoic acid is reacted with salicylaldehyde or a salicylaldehyde derivative in a protective atmosphere. The use method comprises the following steps: different concentrations of sphingosine methanol solutions are prepared, the stock solution of the probe is added into each concentration of the sphingosine methanol solution, and a mixed solution is obtained; the mixed solution is mixed with a matrix methanol solution, is spotted on a target plate, is dried at room temperature, and then is subjected to MALDI analysis; and a standard curve is drawn with different concentrations of the sphingosine in the step S1 as the horizontal coordinate and the MALDI ion signal intensity of the product obtained in the step S1 as the vertical coordinate. The mass spectrum probe provided by the application has high sensitivity, low cost and high throughput.

The present invention relates to a novel and efficient process for the production of sphingolipids via N-acylation of hemolytic sphingolipids, such as o-red-phytosphingosine, salts thereof or analogs thereof. The process comprises the use of an ester as an acylating agent in the presence of a base and in a hydrocarbon solvent, and is particularly useful for the production of ceramides.

A composition has at least one self tanning agent and certain sphingolipids and / or certain sphingoid bases. Cosmetic formulations having the composition with at least one self tanning agent, certain sphingolipids and / or certain sphingoid bases enhance a self tanning effect of a self tanning agent or find application in cosmetic products for tanning of a human skin.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions, including complex sphingolipids, such as monosialic acid ganglioside 1 (GM1), monosialic acid ganglioside 2 (GM2), and monosialic acid ganglioside 3 (GM3). In some embodiments, the present disclosure provides biological production of glycosphingolipids. In still further embodiments, the present disclosure provides for the biological production of gangliosides.

The present invention relates to a lipid system comprising: a) at least one oil, b) at least one ionizable lipid, c) at least one sphingolipid, and d) at least one lipid-polymer, with the proviso is that the lipid system does not comprise cholesterol. The present invention also uses of the lipid system in therapy.

The present invention relates to a novel glycosynthase, especially an endoglycoceramide synthase, and to a method for the glycosylation of sphingolipids.

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.

The present application relates to the field of microbial technology, and particularly relates to a strain of Matuura sphingolipid bacteria HPD1 for degrading high-efficiency fluazifop-butyl acid and application thereof, the Matuura sphingolipid bacteria HPD1 is classified and named as Novosphingobium mathurense , which was preserved in the China General Microbiological Culture Collection Center on May 9, 2026, with a preservation number of CGMCC No. 38610 and a preservation address of No. 1, Beichen West Road, Chaoyang District, Beijing. The Matuura sphingolipid bacteria HPD1 and the microbial inoculant thereof can effectively degrade high-efficiency fluazifop-butyl acid in a wide pH and temperature range, can be used as excellent functional bacteria for degrading pesticide residues, and can be used in the biological remediation of residual high-efficiency fluazifop-butyl acid in water bodies, contaminated soil, coastal wetland sediments and Spartina alterniflora treatment areas, and can provide functional bacteria resources that can be repeatedly obtained and environmentally friendly microbial remediation technology.

Composition (C) comprising, for 100% by mass: 20% to 80% by mass of at least one sphingolipid (a1), 10% to 50% by mass of a digalactosyl diglyceride (a2), and 1% to 30% by mass of at least one phospholipid (a3), for use in a therapeutic treatment method for preventing or limiting sebum production on the scalp. A pharmaceutical composition (Cp) and a food supplement (Ca) comprising said composition (C). A non-therapeutic use of the food supplement (Ca) and a non-therapeutic implementation method.

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.

The application provides application of pig's tooth saponin volatile oil in preparation of a medicine for treating cerebral ischemia-reperfusion injury, and a preparation method of the pig's tooth saponin volatile oil is as follows: pig's tooth saponin decoction pieces are taken, water and n-hexane are added, and volatile oil is obtained through steam distillation; the volatile oil is collected, anhydrous sulfuric acid is added, and water is removed; and the mixture is left overnight to obtain the pig's tooth saponin volatile oil. The prepared pig's tooth saponin volatile oil acts on key target points of VEGFA, SRC, MAPK8, PIK3CA and TNF through active ingredients of paeonol, linalool, methyl eugenol, anethole and eugenol, regulates multiple signal pathways of sphingolipids, TNF and VEGF, inhibits cell oxidative stress injury, inhibits release of inflammatory factors and regulates nerve function, so as to play a role in treating cerebral ischemia-reperfusion injury, and lay a foundation for further in-depth study on a treatment mechanism of pig's tooth saponin in treating 'opening the orifices and connecting the heart and the lung'.

The invention discloses application of a metabolic marker in preparation of a product for monitoring CsA renal toxicity and the product, and the metabolic marker can be used for monitoring CsA renal toxicity and is high in sensitivity, rapid, convenient and accurate and reliable in result. The metabolic marker is one or more of the following substances: phospholipid 18: 1 / 20: 0, phospholipid 20: 1 / 14: 1, lysophospholipid 18: 3, sphingolipid d18: 0 / 16: 1OH, sphingolipid d18: 0 / 24: 1OH and monoacylglycerol 20: 4 / 0: 0 / 0: 0.

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.

The invention discloses a formula of medicinal and edible rice paste capable of tonifying spleen, clearing damp and preventing encephalatrophy. Comprising the following components: 10-20 parts of soybeans, 8-15 parts of small red beans, 6-12 parts of fried coix seeds (fried until the surfaces are light golden yellow and have no burnt spots), 5-10 parts of Chinese yams, 4-8 parts of white poria cocos, 3-7 parts of radix puerariae, 3-6 parts of fried gordon euryale seeds (the frying standard is that the surfaces are slightly burnt and have light burnt fragrance, and the particle size is 2-3mm), 2-5 parts of dried longan, 15-25 parts of millet and 0.5-1.5 parts of shredded dried tangerine peels. The invention belongs to the technical field of medicinal and edible foods, and particularly relates to a medicinal and edible rice paste formula for tonifying spleen, clearing damp and preventing encephalatrophy.

The invention relates to an application of an endothelial Mas receptor agonist in preparation of a medicine for preventing and / or treating metabolism-related fatty liver disease, and aims at endothelial cells to deeply explore a sphingolipid-cell senescence mechanism and prevent and treat the metabolism-related fatty liver disease (MASLD) caused by high fat diet by utilizing the specific agonist effect of the Mas receptor, so that the application of the Mas receptor agonist in preparation of the medicine for preventing and / or treating the metabolism-related fatty liver disease is realized. And a more accurate and effective treatment scheme is provided.

Provided herein are sphingolipid-loaded nanobiologics and uses thereof e.g., in innate immune regulation and the treatment of cancer.

The invention discloses a sphingolipid ceramide N-deacylase mutant. The mutant is formed by amino acid mutation in sphingolipid ceramide N-deacylase as shown in SEQ ID NO.1, and the amino acid mutation is selected from one or more of mutation of the 232 site Tyr, mutation of the 254 site Asn, mutation of the 416 site Phe and mutation of the 592 site Leu. The invention also discloses application of the mutant in preparation of ganglioside derivative molecules by efficient enzymatic synthesis. The stability of the sphingolipid ceramide N-deacylase SCDase mutant is improved, and the pyrolysis chain temperature Tm of the mutant is improved by 5.79 DEG C compared with that of a wild type; the sphingolipid ceramide N-deacylase SCDase mutant provided by the invention enhances the enzyme preparation efficiency of ganglioside, especially for short-chain fatty acids (carbohydrate chain length lt; and 4) the synthetic activity is improved by more than two times, and the result broadens the practical application value of the SCDase enzyme.

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid an

This invention discloses a polysaccharide extracted from *Gynostemma pentaphyllum* using ultrasound-assisted extraction, its preparation method, and its applications, belonging to the field of biomedical technology. This polysaccharide significantly improves peripheral blood counts in mice with cyclophosphamide-induced anemia, alleviates immune organ atrophy and liver damage, and its mechanism of action involves regulating the intestinal flora structure and modulating host sphingolipid and glycerophospholipid metabolic pathways. The preparation method efficiently yields homogeneous polysaccharides from *Gynostemma pentaphyllum*, with optimized process conditions of a liquid-to-solid ratio of 32 mL / g, extraction time of 48 min, and temperature of 60 ℃. The process of this invention is stable and provides a new candidate substance for developing drugs or health foods for the prevention and treatment of chemotherapy-related anemia.

To provide a skin care preparation synergistically improved in moisturizing effect and epidermal barrier function-improving effect by using specific components in combination.SOLUTION: The skin care preparation for external use comprises a citron extract, especially a sphingolipid-containing citron extract, a Rosa rugosa Thunberg flower extract and a fennel extract. The skin care preparation contains one or more kinds of extracts selected from melissa extract, calendula extract, chamomile extract, horsetail extract, horse chestnut extract, hop extract, carrot extract, mistletoe extract, yarrow extract, sage extract, cornflower extract and rosemary extract.SELECTED DRAWING: None

The application discloses a blood marker combination and kit for neurodegenerative diseases of lysosome function axis, and relates to the technical field of biomedical detection. The marker combination is composed of seven markers in three categories: glucocerebrosidase and cathepsin D; sphingolipids and gangliosides; and phosphorylated tau-217 protein, neurofilament light chain protein and glial fibrillary acidic protein. The application also provides an in-vitro diagnostic kit containing specific reagents for detecting the above markers, and constructs a risk assessment model based on a logistic regression or random forest algorithm. The marker combination and kit can be used for early screening, differential diagnosis, disease progression prediction and drug efficacy monitoring of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and neurogenic Gaucher disease, and have the advantages of high sensitivity, high specificity and minimally invasive detection.